|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 10% of metastatic colorectal cancer (mCRC) cases will harbor the BRAF p.V600E mutation (BRAF-mCRC) and have been associated with a poor prognosis.
|
30638691 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation.
|
31566309 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
|
31840683 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Promising clinical trials using combination therapies that inhibit the mitogen-activated protein kinase (MAPK) pathway and alternative active pathways have demonstrated major advances for patients with BRAF V600E-mutated mCRC.
|
31219603 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
|
28972961 |
2017 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
|
27261210 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
|
27956538 |
2016 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.
|
25589621 |
2015 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis.
|
26460303 |
2015 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes.
|
25989278 |
2015 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF codon 594 or 596 mutated mCRCs are different from BRAF V600E ones in terms of molecular features, pathological characteristics and clinical outcome.
|
26153495 |
2015 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an inhibitor of BRAF(V600E) (vemurafenib) is well tolerated and results in a strong disease control in an extensively pretreated mCRC patient.
|
24755613 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
By calculating the ΔC q for real-time traditional PCR, which amplifies all BRAF alleles, versus WTB-PCR, which selectively amplifies mutant BRAF, we demonstrated that among the V600E-positive mCRC patient samples, the percentage of BRAF DNA with the V600E mutation ranged from 0.05 to 52.32%.
|
24500755 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC, we evaluated the role of RAC1b expression as a predictor of chemotherapy efficacy in mCRC.
|
24833563 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be either a complementary or an alternative method to molecular testing in mCRC patients.
|
24798160 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC).
|
24585723 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study aimed to evaluate the relationship between BRAF V600E mutation and the tumor response of anti-EGFR MoAbs for first-line treatment in mCRC patients.
|
24390240 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation plays a negative prognostic role in metastatic colorectal cancer (mCRC), leading to a median Progression Free Survival (PFS) of 4-6months with first-line conventional treatments.
|
24138831 |
2014 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Inadequate evidence was found regarding association of BRAF V600E mutation testing or loss of PTEN expression with improved health outcomes among patients with mCRC undergoing anti-EGFR therapy as compared with patients with tumors bearing wild-type BRAF sequence and PTEN expression levels, respectively.
|
23429431 |
2013 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study we described the KRAS and the BRAF V600E mutation spectra and frequencies in a group of Serbian mCRC specimens.
|
23033302 |
2012 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |